This clinical trial investigates a novel combination therapy for Acute Myeloid Leukemia (AML) involving Tagraxofusp, Azacitidine, and Venetoclax. The trial is sponsored by Dr. Jacqueline Garcia at Dana-Farber Cancer Institute and is currently recruiting participants. The combination aims to address measurable residual disease (MRD) in AML patients, a significant unmet need in the market, as current therapies often fail to eliminate residual disease, leading to relapse. The FDA has previously approved Venetoclax and Azacitidine as a combination therapy for AML, while Tagraxofusp is approved for a different leukemia type. The success of this trial could enhance the competitive positioning of the involved companies, particularly Stemline Therapeutics, which supplies Tagraxofusp. The potential for market expansion hinges on demonstrating improved efficacy and safety over existing therapies, which could lead to significant commercial opportunities in the AML treatment landscape.